← All indications
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
Subtype terms (1)
More specific conditions that are subtypes of Atherosclerosis in the MeSH hierarchy.
- Peripheral Arterial Disease
191 drugs (105 approved, 86 experimental)
Drugs by status
Approved for this indication (11)
Phase 4 trials (78)
- ezetimibe
- acetylcysteine
- maraviroc
- astaxanthin
- berberine
- dabigatran
- epoetin
- fimasartan
- colesevelam
- atenolol
- exenatide
- laropiprant
- enalapril
- folic acid
- gabapentin
- gemfibrozil
- ginseng
- glipizide
- probucol
- hydroxychloroquine
- hemin
- amlodipine
- insulin human
- warfarin
- icosapent ethyl
- indapamide
- insulin detemir
- irbesartan
- pitavastatin
- Molsidomine
- +48 more
Phase 3 trials (73)
- montelukast
- nitroglycerin
- succinobucol
- vitamin e
- bo-653
- canakinumab
- candesartan
- cangrelor
- chlorthalidone
- clazakizumab
- colestipol
- alpha-lipoic acid
- darapladib
- prednisone
- diltiazem
- dulaglutide
- flutemetamol F-18
- fu-zheng-qu-zhuo
- tacrolimus
- paclitaxel
- somatropin
- insulin glargine
- glimepiride
- acarbose
- glycine
- naltrexone
- hydralazine
- cyanocobalamin
- ionis-apo(a)-lrx
- prolycopene
- +43 more
Phase 2 trials (52)
- ringer's lactate
- sodium nitrite
- rilapladib
- vitamin d3
- methylprednisolone
- acp-501
- mln-1202
- clbs12
- conjugated equine estrogens
- progesterone
- vitis vinifera
- tenofovir
- losmapimod
- ritonavir
- k-604
- dronabinol
- meloxicam
- menaquinone
- vitamin c
- pittsburgh compound b
- bms-823778
- prasugrel
- ranolazine
- red blood cells
- revacept
- rilonacept
- darunavir
- resveratrol
- pentoxifylline
- nicotinamide
- +22 more
Phase 1 trials (27)
- metformin
- pbr28
- desmopressin
- anifrolumab
- xl-652
- bms-844421
- gadofosveset trisodium
- indocyanine green
- oleic acid
- bms-962476
- allogeneic hematopoietic stem cells
- Baxdrostat
- sb-568859
- human fecal microbiota
- cu[64]-25%canf-comb
- autologous mesenchymal stem cells
- midazolam
- fish oil
- medi6570
- bt200
- 68ga-fapi
- 99mtccabvcam1-5
- verve-101
- sp-8356
- 68gallium-msa
- azd4144
- udp-003
Other trials (50)
- sodium fluoride (18F)
- cer-001
- cranberry
- etanercept
- garlic
- ethanol
- abciximab
- adenosine
- acetylcholine chloride
- whey protein
- iopamidol
- krill oil
- levocarnitine
- gadopenteate dimeglumine
- naoxintong
- beta-glucans
- cow milk
- phytosterol
- adalimumab
- propranolol
- prulifloxacin
- sarpogrelate
- sevelamer
- sulfur hexafluoride lipid-type a microspheres
- glucose
- ferumoxytol
- ustekinumab
- cellulose
- bilberry
- cod liver oil
- +20 more
Organizations
Organization Involved with Phase 4 Indications (154)
- Abbott
- Regeneron
- Daiichi Sankyo
- Relypsa
- Amgen
- Gilead Sciences
- Novo Nordisk
- Guerbet
- Pfizer
- Novartis
- Bayer
- Dong-A Pharmaceutical
- Hamilton Health Sciences Corporation
- Jeil Pharmaceutical Co., Ltd.
- Korea Ginseng Corporation
- Kos Pharmaceuticals
- Materia Medica Holding
- Solvay
- Therabel Pharma SA/NV
- Accumetrics, Inc.
- Amarin
- Otsuka
- Upsher-Smith Laboratories
- The Dana Foundation
- Swiss National Science Foundation
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Japan Heart Foundation
- National Heart, Lung, and Blood Institute (NHLBI)
- United States Army
- University of Roma La Sapienza
- +124 more
Organization Involved with Phase 3 Indications (82)
- Sankyo
- The Medicines Company
- Roche
- Astellas
- Parke-Davis
- AtheroGenics
- Boston Scientific Corporation
- Chugai
- Esperion Therapeutics
- GlaxoSmithKline
- Immunitor LLC
- Omicron Pharmaceuticals
- Solae, LLC
- National Institutes of Health (NIH)
- National Center for Complementary and Integrative Health (NCCIH)
- National Eye Institute (NEI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Aging (NIA)
- Mead Johnson
- Maastricht University
- Andalusian Initiative for Advanced Therapies
- Brown University
- Harvard University
- Ege University
- Duke University
- Institute for Atherosclerosis Research, Russia
- Joslin Diabetes Center
- Mahidol University
- Malmö University
- +52 more
Organization Involved with Phase 2 Indications (45)
- Takeda
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- AdvanceCor GmbH
- Kowa
- Genentech
- MedImmune
- Genzyme
- BioInvent International AB
- Abionyx
- Resverlogix Corp
- Tallikut Pharmaceuticals, Inc.
- TCA Cellular Therapy
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of Pittsburgh
- AIDS Malignancy Consortium
- Cedars-Sinai Medical Center
- Harbin Medical University
- HonorHealth Research Institute
- Indiana University
- Naestved Hospital
- Queen's University, Belfast
- St. Luke's Hospital, Chesterfield, Missouri
- University of East Anglia
- University of South Carolina
- University of Tennessee
- Shandong University
- Medical University of South Carolina
- Tsinghua University
- Otto Wagner Hospital
- +15 more
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (67)
- Schering-Plough
- Merck KGaA
- Aromtech Ltd.
- Shahid Beheshti University of Medical Sciences
- Region Skane
- Aarhus University
- Rockefeller University
- Allegiance Health
- Appalachian State University
- Canadian Collaborative Research Network
- Cancer Research Network
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Legacy Health System
- Lund University
- Northwell Health
- Sint Franciscus Gasthuis
- Universidade Federal de Santa Maria
- Universidade Federal do Rio Grande do Norte
- University of Eastern Finland
- University of New Mexico
- University of Oklahoma
- University of Bologna
- University of Vermont
- Aichi Gakuin University
- Chinese University of Hong Kong
- Kurume University
- University of Cambridge
- University of Turku
- Ministry of Natioanl Guard Health Affairs
- University of Indonesia
- +37 more